Hypertension Research最新文献

英文中文

Comparison of two validated oscillometric devices in a home-like setup reveals pronounced blood pressure differences and reduced precision 在一个类似家庭的设置中比较两种经过验证的振荡装置，发现明显的血压差异和降低的精度。

IF 4.6 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Hypertension Research

Pub Date : 2026-01-09 DOI: 10.1038/s41440-025-02514-3

Joachim Zahnd, Brian Thompson, Pierre-Antonin Rigon, Patrick Taffé, Gregoire Wuerzner

Home blood pressure monitoring (HBPM) is essential for long-term hypertension management, but its accuracy and reliability is questionable due to user inconsistencies and non-standard usage conditions. This study compared two validated HBPM devices – a wrist-based and a reference upper-arm monitor – in a home-like setup where participants placed the devices themselves. A total of 121 participants underwent four concurrent blood pressure (BP) measurements, with two taken in each arm, followed by a crossover of devices between arms after the initial two readings. Wrist-derived BP readings were higher than upper-arm measurements. With higher blood pressure levels, both devices exhibited greater bias, accompanied by reduced precision in systolic BP measurements. Additionally, hypertension classification showed only moderate agreement (Cohen’s kappa=0.58). The wrist monitor tended to over-diagnose hypertension and exhibited greater variability than the upper-arm device. These findings highlight the need for more guidance and education as well as critical evaluation of home blood pressure measurements provided by patients.

家庭血压监测（HBPM）对于长期高血压治疗至关重要，但由于用户不一致和使用条件不规范，其准确性和可靠性值得怀疑。这项研究比较了两种经过验证的HBPM设备——一种基于手腕的设备和一种参考上臂监测器——在一个类似家庭的设置中，参与者自己放置设备。共有121名参与者同时接受了四次血压（BP）测量，每只手臂测量两次，在最初的两次读数后，在手臂之间交叉使用设备。手腕测得的血压高于上臂测得的血压。当血压水平较高时，两种装置都表现出更大的偏差，同时收缩压测量的精度降低。此外，高血压分类仅显示中度一致性（Cohen’s kappa=0.58）。腕部监测器倾向于过度诊断高血压，并且表现出比上臂装置更大的变异性。这些发现强调需要更多的指导和教育，以及对患者提供的家庭血压测量进行批判性评估。

{"title":"Comparison of two validated oscillometric devices in a home-like setup reveals pronounced blood pressure differences and reduced precision","authors":"Joachim Zahnd, Brian Thompson, Pierre-Antonin Rigon, Patrick Taffé, Gregoire Wuerzner","doi":"10.1038/s41440-025-02514-3","DOIUrl":"10.1038/s41440-025-02514-3","url":null,"abstract":"Home blood pressure monitoring (HBPM) is essential for long-term hypertension management, but its accuracy and reliability is questionable due to user inconsistencies and non-standard usage conditions. This study compared two validated HBPM devices – a wrist-based and a reference upper-arm monitor – in a home-like setup where participants placed the devices themselves. A total of 121 participants underwent four concurrent blood pressure (BP) measurements, with two taken in each arm, followed by a crossover of devices between arms after the initial two readings. Wrist-derived BP readings were higher than upper-arm measurements. With higher blood pressure levels, both devices exhibited greater bias, accompanied by reduced precision in systolic BP measurements. Additionally, hypertension classification showed only moderate agreement (Cohen’s kappa=0.58). The wrist monitor tended to over-diagnose hypertension and exhibited greater variability than the upper-arm device. These findings highlight the need for more guidance and education as well as critical evaluation of home blood pressure measurements provided by patients.","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":"49 3","pages":"969-973"},"PeriodicalIF":4.6,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41440-025-02514-3.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145943097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Challenges in improving the equation for estimating 24-h urinary sodium excretion from casual urine in hypertensive patients taking antihypertensive drugs: addressing overestimation, especially at low sodium excretion levels 改善高血压患者服用降压药后24小时尿钠排泄量估算公式的挑战：解决高估问题，特别是在低钠排泄水平下。

IF 4.6 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Hypertension Research

Pub Date : 2026-01-09 DOI: 10.1038/s41440-025-02539-8

Morio Matsumoto, Kimika Arakawa, Kai Asai, Takuya Tsuchihasi

The estimation formula by Tanaka et al. for predicting the 24-h urinary sodium (Na) excretion (24Na) from a single causal urine sample is widely used. However, it overestimates values in the low 24Na range. We aimed to develop a formula to improve the accuracy, particularly for samples with 24Na < 2 g/day. Stored data from 187 hypertensive patients (mean age, 66.1 years; 56.7% female) who underwent both 24-h home urine collection and a fasting morning causal urine test the following day were analyzed. We used a machine learning approach to extract conditional branches based on the threshold relationships among the variables. The proposed estimation formula was constructed by adding a correction term to the Na/Creatinine(Cr) ratio in Tanaka’s formula and the modified formula was applied to each conditional branch. The correction terms included body mass index (BMI), age, and concentration of causal urine Na and were applied in different forms according to each branch. Compared with the Tanaka method, our method improved the agreement rate by ~25% and reduced the disagreement rate by 25% in samples with 24Na < 2 g/day. The correlation coefficient was higher (Ours: 0.51, Tanaka: 0.29), the range of error with 24Na was narrower (Ours: 4.89, Tanaka: 5.69), and the percentage of absolute errors for <1 g improved by 9.8%. Although developed from a specific dataset, our formula is useful for low-24Na samples prone to misestimation by the conventional formula and may improve the accuracy of dietary salt intake assessments from causal urine.

Tanaka等人用于预测单个因果尿样24小时尿钠（Na）排泄（24Na）的估算公式被广泛使用。然而，它高估了低24Na范围内的值。我们的目标是开发一种公式来提高准确性，特别是对于含有24Na的样品

{"title":"Challenges in improving the equation for estimating 24-h urinary sodium excretion from casual urine in hypertensive patients taking antihypertensive drugs: addressing overestimation, especially at low sodium excretion levels","authors":"Morio Matsumoto, Kimika Arakawa, Kai Asai, Takuya Tsuchihasi","doi":"10.1038/s41440-025-02539-8","DOIUrl":"10.1038/s41440-025-02539-8","url":null,"abstract":"The estimation formula by Tanaka et al. for predicting the 24-h urinary sodium (Na) excretion (24Na) from a single causal urine sample is widely used. However, it overestimates values in the low 24Na range. We aimed to develop a formula to improve the accuracy, particularly for samples with 24Na < 2 g/day. Stored data from 187 hypertensive patients (mean age, 66.1 years; 56.7% female) who underwent both 24-h home urine collection and a fasting morning causal urine test the following day were analyzed. We used a machine learning approach to extract conditional branches based on the threshold relationships among the variables. The proposed estimation formula was constructed by adding a correction term to the Na/Creatinine(Cr) ratio in Tanaka’s formula and the modified formula was applied to each conditional branch. The correction terms included body mass index (BMI), age, and concentration of causal urine Na and were applied in different forms according to each branch. Compared with the Tanaka method, our method improved the agreement rate by ~25% and reduced the disagreement rate by 25% in samples with 24Na < 2 g/day. The correlation coefficient was higher (Ours: 0.51, Tanaka: 0.29), the range of error with 24Na was narrower (Ours: 4.89, Tanaka: 5.69), and the percentage of absolute errors for <1 g improved by 9.8%. Although developed from a specific dataset, our formula is useful for low-24Na samples prone to misestimation by the conventional formula and may improve the accuracy of dietary salt intake assessments from causal urine.","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":"49 2","pages":"539-549"},"PeriodicalIF":4.6,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145943059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent advances and emerging perspectives in vascular and cardiovascular research: A 2025 update 血管和心血管研究的最新进展和新兴观点：2025年更新。

IF 4.6 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Hypertension Research

Pub Date : 2026-01-09 DOI: 10.1038/s41440-025-02540-1

Shinji Kishimoto, Yukihito Higashi

Cardiovascular diseases (CVDs) have been a major cause of global morbidity and mortality, necessitating continuous innovation in diagnostic methods, better mechanistic understanding, and the development of risk stratification strategies. This review summarizes significant updates in vascular and cardiovascular health from 2024 to 2025, focusing on novel non-invasive assessment technologies, deeper insights into molecular and cellular pathophysiology, and effective approaches to clinical risk assessment. Key advancements include the development and validation of artificial intelligence-driven models for vascular age assessment, plethysmographic methods for endothelial function evaluation, and refined pulse wave velocity measurements for proximal aortic stiffness. Mechanistic studies have further investigated the roles of long noncoding RNAs, mitochondrial dynamics, and Piezo ion channels in various CVD pathologies. Clinically, new evidence supports the importance of central arterial stiffness in atrial myopathy, the association of pulse wave velocity with cerebral microbleeds, and the prognostic value of supine hypertension and combined vascular biomarkers, such as the cardio-ankle vascular index and ankle-brachial index. Furthermore, these updates will improve our understanding of vascular health and provide novel approaches to early detection, personalized intervention, and improving patient outcomes in the management of CVD.

心血管疾病（cvd）已成为全球发病率和死亡率的主要原因，因此需要不断创新诊断方法，更好地了解机制，并制定风险分层策略。本文综述了2024年至2025年血管和心血管健康领域的重大进展，重点介绍了新的无创评估技术、对分子和细胞病理生理学的更深入了解以及临床风险评估的有效方法。主要进展包括用于血管年龄评估的人工智能驱动模型的开发和验证，用于内皮功能评估的体积测量方法，以及用于近端主动脉僵硬的精细脉搏波速度测量。机制研究进一步探讨了长链非编码rna、线粒体动力学和压电离子通道在各种CVD病理中的作用。临床上，新的证据支持中央动脉硬度在心房肌病中的重要性，脉搏波速度与脑微出血的相关性，以及仰卧高血压和联合血管生物标志物（如心踝血管指数和踝肱指数）的预后价值。此外，这些更新将提高我们对血管健康的理解，为心血管疾病的早期发现、个性化干预和改善患者预后提供新方法。

{"title":"Recent advances and emerging perspectives in vascular and cardiovascular research: A 2025 update","authors":"Shinji Kishimoto, Yukihito Higashi","doi":"10.1038/s41440-025-02540-1","DOIUrl":"10.1038/s41440-025-02540-1","url":null,"abstract":"Cardiovascular diseases (CVDs) have been a major cause of global morbidity and mortality, necessitating continuous innovation in diagnostic methods, better mechanistic understanding, and the development of risk stratification strategies. This review summarizes significant updates in vascular and cardiovascular health from 2024 to 2025, focusing on novel non-invasive assessment technologies, deeper insights into molecular and cellular pathophysiology, and effective approaches to clinical risk assessment. Key advancements include the development and validation of artificial intelligence-driven models for vascular age assessment, plethysmographic methods for endothelial function evaluation, and refined pulse wave velocity measurements for proximal aortic stiffness. Mechanistic studies have further investigated the roles of long noncoding RNAs, mitochondrial dynamics, and Piezo ion channels in various CVD pathologies. Clinically, new evidence supports the importance of central arterial stiffness in atrial myopathy, the association of pulse wave velocity with cerebral microbleeds, and the prognostic value of supine hypertension and combined vascular biomarkers, such as the cardio-ankle vascular index and ankle-brachial index. Furthermore, these updates will improve our understanding of vascular health and provide novel approaches to early detection, personalized intervention, and improving patient outcomes in the management of CVD.","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":"49 3","pages":"740-748"},"PeriodicalIF":4.6,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41440-025-02540-1.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145943390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Twin pregnancies are risk factors for both early- and late-onset hypertensive disorders of pregnancy: the Japan Environment and Children's study. 双胎妊娠是妊娠早期和晚期高血压疾病的危险因素：日本环境与儿童研究。

IF 4.6 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Hypertension Research

Pub Date : 2026-01-09 DOI: 10.1038/s41440-025-02502-7

Kazuma Tagami, Noriyuki Iwama, Hirotaka Hamada, Hasumi Tomita, Natsumi Kumagai, Hongxin Wang, Seiya Izumi, Zen Watanabe, Mami Ishikuro, Taku Obara, Hirohito Metoki, Yuichiro Miura, Chiharu Ota, Shinichi Kuriyama, Takahiro Arima, Nobuo Yaegashi, Masatoshi Saito

This study investigated the associations of twin pregnancies with early-onset (EO)- and late-onset (LO)-hypertensive disorders of pregnancy (HDP). Totally, 86,717 pregnant women were included in a prospective birth cohort study. The associations of dichorionic diamniotic (DD)- and monochorionic diamniotic (MD)-twin pregnancies with EO-HDP (Diagnosed from 20 to <34 weeks of gestation) and LO-HDP (Diagnosed at ≥34 weeks of gestation) were analyzed using a multinomial logistic regression model. Compared with singleton pregnancies, both DD- and MD-twin pregnancies had significantly higher odds for EO- and LO-HDP. The adjusted odds ratios (aORs) for EO-HDP were 2.05 (95% confidence interval [Cl]: 1.51-2.78) in DD-twin pregnancies and 2.80 (95% Cl: 2.01-3.90) in MD-twin pregnancies, respectively. Also, the aORs for LO-HDP were 1.32 (95% CI: 1.03-1.69) in DD-twin pregnancies and 1.64 (95% Cl: 1.24-2.17) in MD-twin pregnancies, respectively. Although no statistically significant differences were observed, MD-twin pregnancies tended to have higher odds for both EO- and LO-onset HDP compared with DD-twin pregnancies. In conclusion, both DD- and MD-twin pregnancies are risk factors for the development of EO- and LO-HDP. We showed that both dichorionic diamniotic and monochorionic diamniotic twin pregnancies are risk factors for the development of early-onset and late-onset hypertensive disorders of pregnancy.

本研究探讨了双胎妊娠与早发性（EO）和晚发性（LO）妊娠高血压疾病（HDP）的关系。一项前瞻性出生队列研究共纳入了86717名孕妇。双绒毛膜双羊膜症（DD）和单绒毛膜双羊膜症（MD）双胎妊娠与EO-HDP的关系（诊断时间从20年到20年）

{"title":"Twin pregnancies are risk factors for both early- and late-onset hypertensive disorders of pregnancy: the Japan Environment and Children's study.","authors":"Kazuma Tagami, Noriyuki Iwama, Hirotaka Hamada, Hasumi Tomita, Natsumi Kumagai, Hongxin Wang, Seiya Izumi, Zen Watanabe, Mami Ishikuro, Taku Obara, Hirohito Metoki, Yuichiro Miura, Chiharu Ota, Shinichi Kuriyama, Takahiro Arima, Nobuo Yaegashi, Masatoshi Saito","doi":"10.1038/s41440-025-02502-7","DOIUrl":"https://doi.org/10.1038/s41440-025-02502-7","url":null,"abstract":"This study investigated the associations of twin pregnancies with early-onset (EO)- and late-onset (LO)-hypertensive disorders of pregnancy (HDP). Totally, 86,717 pregnant women were included in a prospective birth cohort study. The associations of dichorionic diamniotic (DD)- and monochorionic diamniotic (MD)-twin pregnancies with EO-HDP (Diagnosed from 20 to <34 weeks of gestation) and LO-HDP (Diagnosed at ≥34 weeks of gestation) were analyzed using a multinomial logistic regression model. Compared with singleton pregnancies, both DD- and MD-twin pregnancies had significantly higher odds for EO- and LO-HDP. The adjusted odds ratios (aORs) for EO-HDP were 2.05 (95% confidence interval [Cl]: 1.51-2.78) in DD-twin pregnancies and 2.80 (95% Cl: 2.01-3.90) in MD-twin pregnancies, respectively. Also, the aORs for LO-HDP were 1.32 (95% CI: 1.03-1.69) in DD-twin pregnancies and 1.64 (95% Cl: 1.24-2.17) in MD-twin pregnancies, respectively. Although no statistically significant differences were observed, MD-twin pregnancies tended to have higher odds for both EO- and LO-onset HDP compared with DD-twin pregnancies. In conclusion, both DD- and MD-twin pregnancies are risk factors for the development of EO- and LO-HDP. We showed that both dichorionic diamniotic and monochorionic diamniotic twin pregnancies are risk factors for the development of early-onset and late-onset hypertensive disorders of pregnancy.","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145943356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Definition and classification of office and out-of-office blood pressure across recent guidelines 最近指南中办公室和办公室外血压的定义和分类。

IF 4.6 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Hypertension Research

Pub Date : 2026-01-09 DOI: 10.1038/s41440-025-02543-y

Kei Asayama, Masahiro Kikuya, Takayoshi Ohkubo

引用次数: 0

The conservative–challenging paradigm of antihypertensive therapy in JSH2025: a comparative perspective with contemporary Western guidelines JSH2025中抗高血压治疗的保守挑战范式：与当代西方指南的比较视角

IF 4.6 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Hypertension Research

Pub Date : 2026-01-09 DOI: 10.1038/s41440-025-02545-w

Hisashi Kai

引用次数: 0

Accelerated epigenetic age in hypertension: a systematic review and meta-analysis. 高血压的表观遗传年龄加速：一项系统综述和荟萃分析。

IF 4.6 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Hypertension Research

Pub Date : 2026-01-09 DOI: 10.1038/s41440-025-02470-y

C Dollin, M Ward, M Y C Stafford, E Krason-Kidzinska, Lauren Crawford, H McNulty, Frank Barry, M Murphy, D J Lees-Murdock

Chronological age is a well-established risk factor for Hypertension (HTN), yet while biological ageing markers such as epigenetic age acceleration (EAA), have been associated with HTN, findings are inconsistent. This study aimed to conduct a systematic review and meta-analysis to evaluate the association between EAA, HTN and blood pressure (BP) to provide an understanding of the role of EAA in HTN development and progression. Six databases were searched, and studies which reported associations between DNA and HTN, and/or BP were included. Functional enrichment analysis was conducted using DAVID and STRING to elucidate underlying molecular pathways. From 4334 studies, 165 met the inclusion criteria. Qualitative analysis indicated that 17.0% of studies reporting global methylation and 49.1% of studies reporting gene-specific methylation demonstrated significant associations with HTN and/or BP. A random effects meta-analysis of 16,136 participants from 8 studies using three epigenetic clock algorithms demonstrated that HTN was associated with increased EAA (β: 0.29, 95%Cl: 0.15-0.43; P < 0.0001). All three individual epigenetic clocks demonstrated a positive association between clinically measured HTN and EAA (Horvath β: 0.33, 95%Cl: 0.08-0.58, P = 0.010; Hannum β: 0.64, 95%Cl: 0.09-1.20; PhenoAge β: 1.21, 95%Cl: 0.56-1.86), whereas this relationship was not clear when using self-reported HTN. This study is the first to systematically demonstrate that HTN is associated with EAA. We recommend the use of clinically measured over self-reported HTN in appropriately powered studies of epigenetic age to obtain an accurate understanding of BP regulation/HTN on the epigenome, supporting pathways to translation and development of novel therapeutic targets for HTN.

实足年龄是高血压（HTN）的一个公认的危险因素，然而，尽管表观遗传年龄加速（EAA）等生物衰老标志物与HTN有关，但研究结果并不一致。本研究旨在通过系统回顾和荟萃分析来评估EAA、HTN和血压（BP）之间的关系，以了解EAA在HTN发生和进展中的作用。我们检索了6个数据库，并纳入了报道DNA与HTN和/或BP之间关联的研究。利用DAVID和STRING进行功能富集分析，以阐明潜在的分子途径。从4334项研究中，有165项符合纳入标准。定性分析表明，17.0%的报告全球甲基化的研究和49.1%的报告基因特异性甲基化的研究显示与HTN和/或BP有显著关联。采用三种表观遗传时钟算法对8项研究的16,136名参与者进行随机效应荟萃分析，结果表明，HTN与EAA增加相关(β: 0.29, 95%Cl: 0.15-0.43

{"title":"Accelerated epigenetic age in hypertension: a systematic review and meta-analysis.","authors":"C Dollin, M Ward, M Y C Stafford, E Krason-Kidzinska, Lauren Crawford, H McNulty, Frank Barry, M Murphy, D J Lees-Murdock","doi":"10.1038/s41440-025-02470-y","DOIUrl":"10.1038/s41440-025-02470-y","url":null,"abstract":"Chronological age is a well-established risk factor for Hypertension (HTN), yet while biological ageing markers such as epigenetic age acceleration (EAA), have been associated with HTN, findings are inconsistent. This study aimed to conduct a systematic review and meta-analysis to evaluate the association between EAA, HTN and blood pressure (BP) to provide an understanding of the role of EAA in HTN development and progression. Six databases were searched, and studies which reported associations between DNA and HTN, and/or BP were included. Functional enrichment analysis was conducted using DAVID and STRING to elucidate underlying molecular pathways. From 4334 studies, 165 met the inclusion criteria. Qualitative analysis indicated that 17.0% of studies reporting global methylation and 49.1% of studies reporting gene-specific methylation demonstrated significant associations with HTN and/or BP. A random effects meta-analysis of 16,136 participants from 8 studies using three epigenetic clock algorithms demonstrated that HTN was associated with increased EAA (β: 0.29, 95%Cl: 0.15-0.43; P < 0.0001). All three individual epigenetic clocks demonstrated a positive association between clinically measured HTN and EAA (Horvath β: 0.33, 95%Cl: 0.08-0.58, P = 0.010; Hannum β: 0.64, 95%Cl: 0.09-1.20; PhenoAge β: 1.21, 95%Cl: 0.56-1.86), whereas this relationship was not clear when using self-reported HTN. This study is the first to systematically demonstrate that HTN is associated with EAA. We recommend the use of clinically measured over self-reported HTN in appropriately powered studies of epigenetic age to obtain an accurate understanding of BP regulation/HTN on the epigenome, supporting pathways to translation and development of novel therapeutic targets for HTN.","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145943458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Supine blood pressure measurement and its emerging role in cardiovascular risk stratification 仰卧位血压测量及其在心血管危险分层中的新作用。

IF 4.6 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Hypertension Research

Pub Date : 2026-01-09 DOI: 10.1038/s41440-025-02531-2

Takahiro Komori

The measurement of an individual’s blood pressure (BP) while he or she is in a seated position is the standard BP measurement method. The significance of BP measurements obtained from an individual while he or she is in the supine position has also been described. Supine BP values are usually lower than seated BP values, and thus the condition of high supine BP is abnormal and called ‘supine hypertension.’ Although the mechanisms that underlie supine hypertension are not completely understood, it has been speculated that fluid retention and abnormal sympathetic nervous activity can lead to supine hypertension. Hypertension-mediated organ damage and cardiovascular events have been shown to be associated with supine hypertension; not only supine hypertension with neurogenic orthostatic hypotension but also supine hypertension without it. The treatment of supine hypertension has not been established. Considering the pathophysiological background of this condition, the use of antihypertensive drugs and bedtime dosing may be effective. Further research is necessary to clarify the significance of supine hypertension and to establish the optimal treatment for this condition.

当一个人坐着时测量他或她的血压是标准的血压测量方法。从个人获得的血压测量的意义，而他或她在仰卧位也已描述。仰卧位血压值通常低于坐位血压值，因此仰卧位血压高的情况是不正常的，称为“仰卧位高血压”。虽然仰卧位高血压的机制尚不完全清楚，但据推测，液体潴留和异常交感神经活动可导致仰卧位高血压。高血压介导的器官损伤和心血管事件已被证明与仰卧位高血压相关；既有伴神经源性直立性低血压的仰卧位高血压，也有不伴神经源性直立性低血压的仰卧位高血压。仰卧位高血压的治疗方法尚未确定。考虑到这种情况的病理生理背景，使用降压药和睡前给药可能是有效的。需要进一步的研究来阐明仰卧位高血压的重要性，并建立最佳的治疗方法。

{"title":"Supine blood pressure measurement and its emerging role in cardiovascular risk stratification","authors":"Takahiro Komori","doi":"10.1038/s41440-025-02531-2","DOIUrl":"10.1038/s41440-025-02531-2","url":null,"abstract":"The measurement of an individual’s blood pressure (BP) while he or she is in a seated position is the standard BP measurement method. The significance of BP measurements obtained from an individual while he or she is in the supine position has also been described. Supine BP values are usually lower than seated BP values, and thus the condition of high supine BP is abnormal and called ‘supine hypertension.’ Although the mechanisms that underlie supine hypertension are not completely understood, it has been speculated that fluid retention and abnormal sympathetic nervous activity can lead to supine hypertension. Hypertension-mediated organ damage and cardiovascular events have been shown to be associated with supine hypertension; not only supine hypertension with neurogenic orthostatic hypotension but also supine hypertension without it. The treatment of supine hypertension has not been established. Considering the pathophysiological background of this condition, the use of antihypertensive drugs and bedtime dosing may be effective. Further research is necessary to clarify the significance of supine hypertension and to establish the optimal treatment for this condition.","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":"49 3","pages":"734-739"},"PeriodicalIF":4.6,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145943382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Blood pressure management in stroke: comparative review of the 2025 AHA/ACC/AANP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM, 2024 ESC, 2023 ESH, and 2025 JSH guidelines 卒中血压管理：2025 AHA/ACC/AANP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM、2024 ESC、2023 ESH和2025 JSH指南的比较回顾

IF 4.6 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Hypertension Research

Pub Date : 2026-01-09 DOI: 10.1038/s41440-025-02517-0

Masatoshi Koga

Hypertension is the primary modifiable risk factor for both ischemic stroke and intracerebral hemorrhage (ICH), yet recommendations for blood pressure (BP) management vary across contemporary guidelines. This narrative review compares BP targets and therapeutic strategies in the 2025 American Heart Association (AHA), 2024 European Society of Cardiology (ESC), 2023 European Society of Hypertension (ESH), and 2025 Japanese Society of Hypertension (JSH) guidelines, with emphasis on acute and chronic phases of ischemic stroke and ICH. In acute ischemic stroke without reperfusion therapy, all four guidelines discourage routine BP lowering unless systolic BP (SBP) is ≥220 mmHg or diastolic BP ≥ 120 (110) mmHg, and then recommend only modest reductions of about 15% within 24 hours. For patients receiving IV thrombolysis or mechanical thrombectomy, the guidelines converge on pre-treatment BP<185/110 mmHg and maintenance <180/105 mmHg during the first 24 hours, with JSH specifying micro-infusion calcium channel blockers as preferred agents. In chronic ischemic stroke, AHA, ESH, and JSH generally endorse BP<130/80 mmHg, whereas ESC prioritizes an SBP range of 120-9 mmHg. For acute ICH, all guidelines support rapid but carefully titrated SBP reduction toward approximately 140 mmHg, while emphasizing avoidance of overshoot, large variability, and excessive early declines, particularly when baseline SBP exceeds 220 mmHg in the AHA and ESC guidelines. Long-term after ICH, targets of <130/80 mmHg are widely recommended. Thiazide diuretics, ACE inhibitors, and angiotensin receptor blockers remain foundational for secondary prevention, with calcium channel blockers central to acute parenteral therapy and β-blockers reserved for specific indications. Despite regional nuances, the guidelines converge on conservative acute management in ischemic stroke, proactive early lowering in ICH, and intensive long-term BP control as the global benchmark for secondary cerebrovascular prevention.

高血压是缺血性卒中和脑出血（ICH）的主要可改变的危险因素，但不同指南对血压（BP）管理的建议各不相同。这篇叙述性综述比较了2025年美国心脏协会（AHA）、2024年欧洲心脏病学会（ESC）、2023年欧洲高血压学会（ESH）和2025年日本高血压学会（JSH）指南中的血压靶点和治疗策略，重点是缺血性卒中和脑出血的急性和慢性期。在没有再灌注治疗的急性缺血性卒中中，所有四项指南都不建议常规降压，除非收缩压(SBP)≥220 mmHg或舒张压≥120 (110)mmHg，然后建议在24小时内仅适度降低约15%。对于接受静脉溶栓或机械取栓的患者，指南集中于治疗前血压

{"title":"Blood pressure management in stroke: comparative review of the 2025 AHA/ACC/AANP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM, 2024 ESC, 2023 ESH, and 2025 JSH guidelines","authors":"Masatoshi Koga","doi":"10.1038/s41440-025-02517-0","DOIUrl":"10.1038/s41440-025-02517-0","url":null,"abstract":"Hypertension is the primary modifiable risk factor for both ischemic stroke and intracerebral hemorrhage (ICH), yet recommendations for blood pressure (BP) management vary across contemporary guidelines. This narrative review compares BP targets and therapeutic strategies in the 2025 American Heart Association (AHA), 2024 European Society of Cardiology (ESC), 2023 European Society of Hypertension (ESH), and 2025 Japanese Society of Hypertension (JSH) guidelines, with emphasis on acute and chronic phases of ischemic stroke and ICH. In acute ischemic stroke without reperfusion therapy, all four guidelines discourage routine BP lowering unless systolic BP (SBP) is ≥220 mmHg or diastolic BP ≥ 120 (110) mmHg, and then recommend only modest reductions of about 15% within 24 hours. For patients receiving IV thrombolysis or mechanical thrombectomy, the guidelines converge on pre-treatment BP<185/110 mmHg and maintenance <180/105 mmHg during the first 24 hours, with JSH specifying micro-infusion calcium channel blockers as preferred agents. In chronic ischemic stroke, AHA, ESH, and JSH generally endorse BP<130/80 mmHg, whereas ESC prioritizes an SBP range of 120-9 mmHg. For acute ICH, all guidelines support rapid but carefully titrated SBP reduction toward approximately 140 mmHg, while emphasizing avoidance of overshoot, large variability, and excessive early declines, particularly when baseline SBP exceeds 220 mmHg in the AHA and ESC guidelines. Long-term after ICH, targets of <130/80 mmHg are widely recommended. Thiazide diuretics, ACE inhibitors, and angiotensin receptor blockers remain foundational for secondary prevention, with calcium channel blockers central to acute parenteral therapy and β-blockers reserved for specific indications. Despite regional nuances, the guidelines converge on conservative acute management in ischemic stroke, proactive early lowering in ICH, and intensive long-term BP control as the global benchmark for secondary cerebrovascular prevention.","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":"49 3","pages":"984-987"},"PeriodicalIF":4.6,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41440-025-02517-0.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145943135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancing evidence-based blood pressure targets in JSH2025 推进《JSH2025》中的循证血压目标。

IF 4.6 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Hypertension Research

Pub Date : 2026-01-09 DOI: 10.1038/s41440-025-02518-z

Atsushi Sakima, Nobuhito Hirawa, Yusuke Ohya

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Hypertension Research

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀